Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius) (Sirius)

10 september 2026 uppdaterad av: Windward Bio

A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of WIN378 in Participants With Moderate - Severe Chronic Obstructive Pulmonary Disease

This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD). WIN378 blocks the action of a protein called TSLP that causes inflammation in the lung and may contribute to COPD control and symptoms. The study will test how doses of WIN378 are handled by the body (pharmacokinetics) and assess the safety of the medicine and markers of COPD inflammation in exhaled breath and blood, lung function and COPD control (pharmacodynamics)

Studieöversikt

Status

Rekrytering

Detaljerad beskrivning

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, and pharmacokinetics of WIN378 in adult participants with moderate - severe chronic obstructive pulmonary disease (COPD). Participants will continue their standard background COPD therapy. Eligible participants will receive doses of WIN378 or placebo over a 24-week treatment period.

Studietyp

Interventionell

Inskrivning (Beräknad)

105

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Buenos Aires
      • Buenos Aires, Buenos Aires, Argentina, C1023AAB
        • Rekrytering
        • WB Contracted Clinical Research Site
      • Buenos Aires, Buenos Aires, Argentina, C1028AAP
        • Rekrytering
        • WB Contracted Clinical Research Site
      • Buenos Aires, Buenos Aires, Argentina, C1122AAK
        • Rekrytering
        • WB Contracted Clinical Research Site
      • Buenos Aires, Buenos Aires, Argentina, C1425BEN
        • Rekrytering
        • WB Contracted Clinical Research Site
      • Buenos Aires, Buenos Aires, Argentina, C1425FVH
        • Rekrytering
        • WB Contracted Clinical Research Site
      • Buenos Aires, Buenos Aires, Argentina, C142ABP
        • Rekrytering
        • WB Contracted Clinical Research Site
    • Buenos Aires F.D.
      • Buenos Aires, Buenos Aires F.D., Argentina, C1414AIF
        • Rekrytering
        • WB Contracted Clinical Research Site
      • Buenos Aires, Buenos Aires F.D., Argentina, C1426ABP
        • Rekrytering
        • WB Contracted Clinical Research Site
    • Mendoza Province
      • Buenos Aires, Mendoza Province, Argentina, M5500AXR
        • Rekrytering
        • WB Contracted Clinical Research Site
      • Mendoza, Mendoza Province, Argentina, M5500CBA
        • Rekrytering
        • WB Contracted Clinical Research Site
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, S2000KZD
        • Rekrytering
        • WB Contracted Clinical Research Site
      • Rosario, Santa Fe Province, Argentina, S2013OJN
        • Rekrytering
        • WB Contracted Clinical Research Site
      • Santa Fe, Santa Fe Province, Argentina, S3000ASF
        • Rekrytering
        • WB Contracted Clinical Research Site
    • California
      • Los Angeles, California, Förenta staterna, 93534
        • Rekrytering
        • WB Contracted Clinical Research Site
    • Florida
      • Miami Lakes, Florida, Förenta staterna, 33014
        • Rekrytering
        • WB Contracted Clinical Research Site
    • Massachusetts
      • North Dartmouth, Massachusetts, Förenta staterna, 02747
        • Rekrytering
        • WB Contracted Clinical Research Site
    • North Carolina
      • Charlotte, North Carolina, Förenta staterna, 28277
        • Rekrytering
        • WB Contracted Clinical Research Site
    • Oregon
      • Medford, Oregon, Förenta staterna, 97504
        • Rekrytering
        • WB Contracted Clinical Research Site
    • Pennsylvania
      • DuBois, Pennsylvania, Förenta staterna, 15801
        • Rekrytering
        • WB Contracted Clinical Research Site
    • Texas
      • McKinney, Texas, Förenta staterna, 75069
        • Rekrytering
        • WB Contracted Clinical Research Site
      • Waxahachie, Texas, Förenta staterna, 75165
        • Rekrytering
        • WB Contracted Clinical Research Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Adults aged 40 to 80 years
  • Post-BD spirometry at screening FEV1/FVC < 0.70 and FEV1 30-80% predicted
  • On stable triple inhaled therapy (ICS/LABA/LAMA) for ≥ 3 months
  • Former smoker (≥ 10 pack-year history) and abstinence from smoking for ≥ 6 months
  • Elevated eosinophil count
  • Weight/BMI within allowed range

Exclusion Criteria:

  • Clinically significant pulmonary disease other than chronic obstructive pulmonary disease (COPD)
  • Clinically significant comorbid medical conditions or infections that, in the investigator's judgment, could affect participant safety or interfere with study conduct
  • Clinically significant cardiovascular disease
  • Recent respiratory infection or COPD exacerbation
  • Exposure to approved or experimental biologic therapies for COPD with less than 5 half-life washout period
  • Pregnancy or breastfeeding
  • Smoking or diagnosed substance use disorder
  • Any condition or circumstance that, in the investigator's opinion, would make participation unsafe or compromise study integrity

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: WIN378 Dose 1
WIN378 SC injections will be administered
WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval
Experimentell: WIN378 Dose 2
WIN378 SC injections will be administered
WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval
Experimentell: Placebo
Placebo SC injections will be administered
Placebo matching WIN378

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of participants with Adverse Events (AEs)
Tidsram: Week 0 - Week 36
Week 0 - Week 36
Number of participants with Serious Adverse Events (SAEs)
Tidsram: Week 0 - Week 36
Week 0 - Week 36
Change from baseline in systolic blood pressure (mmHg)
Tidsram: Week 0 - Week 36
Week 0 - Week 36
Change from baseline in diastolic blood pressure (mmHg)
Tidsram: Week 0 - Week 36
Week 0 - Week 36
Change from baseline in pulse rate (beats/minute)
Tidsram: Week 0 - Week 36
Week 0 - Week 36
Change from baseline in respiratory rate (breaths/minute)
Tidsram: Week 0 - Week 36
Week 0 - Week 36
Change from baseline in oxygen saturation (%)
Tidsram: Week 0 - Week 36
Week 0 - Week 36
Change from baseline in body weight (kg)
Tidsram: Week 0 - Week 36
Week 0 - Week 36
Change from baseline in body mass index (kg/m^2)
Tidsram: Week 0 - Week 36
Week 0 - Week 36
Change from baseline in body temperature (°C)
Tidsram: Week 0- Week 36
Week 0- Week 36
Change from baseline in clinical chemistry laboratory assessments
Tidsram: Week 0 - Week 36
Clinical chemistry assessments will include serum chemistry (such as sodium, potassium, urea, creatinine) and liver function parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin.
Week 0 - Week 36
Change from baseline in haematology laboratory parameters
Tidsram: Week 0 - Week 36
Haematology assessments will include haemoglobin, white blood cell count, differential white blood cell counts and platelet count
Week 0 - Week 36
Change from baseline in coagulation laboratory parameters
Tidsram: Week 0 - Week 36
Coagulation assessments will include activated partial thromboplastin time, international normalised ratio, prothrombin time and fibrinogen
Week 0 - Week 36
Change from baseline in urinalysis parameters
Tidsram: Week 0 - Week 36
Urinalysis assessments will include protein, pH, blood, glucose and leucocytes
Week 0 - Week 36
Change from baseline in electrocardiogram QT interval
Tidsram: Week 0 - Week 36
Electrocardiogram assessments will include evaluation of QT interval corrected using Fridericia's formula (QTcF)
Week 0 - Week 36
WIN378 Serum concentration (PK)
Tidsram: Week 0 to week 36
Week 0 to week 36

Sekundära resultatmått

Resultatmått
Tidsram
Change from baseline in Blood Eosinophil Count
Tidsram: Week 0 to Week 24
Week 0 to Week 24
Change in Fractional Exhaled Nitric Oxide (FeNO)
Tidsram: Week 0 to Week 24
Week 0 to Week 24
Change in Pre and Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Tidsram: Week 0 to Week 24
Week 0 to Week 24
Change in Pre and Post Bronchodilator Forced Vital Capacity (FVC)
Tidsram: Week 0 to Week 24
Week 0 to Week 24
Incidence and magnitude of anti-drug antibodies to WIN 378
Tidsram: Week 0 to Week 36
Week 0 to Week 36

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Studierektor: Omar Khwaja, MD, Windward Bio

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Användbara länkar

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

2 juni 2026

Primärt slutförande (Beräknad)

17 december 2027

Avslutad studie (Beräknad)

7 januari 2028

Studieregistreringsdatum

Först inskickad

2 juni 2026

Först inskickad som uppfyllde QC-kriterierna

9 juni 2026

Första postat (Faktisk)

12 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

15 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera